Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials

<div>Analysis of a dose cut-off (310 × 10<sup>6</sup> BM-MNCs injected) and outcomes after 180 days. Patients with good outcomes had no or mild disability (mRS of 0–2). Values are expressed in millions of cells.</div>

Stem Cells International

fig2

Figure 2

Figure 2: Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials 

Figure 2 | Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials 